The difference between dacomitinib and dacomitinib

Dacomitinib and dacomitinib (Dacomitinib) actually refer to the same drug, so there is no difference between them in terms of drug ingredients, mechanism of action, efficacy and clinical application. The drug is primarily used to treat certain types of non-small cell lung cancer, specifically those with mutations in the epidermal growth factor receptor (EGFR).

The mechanism of action of dacomitinib is mainly reflected in its irreversible binding toEGFR protein. This binding method is similar to afatinib, but compared with the first-generation EGFR inhibitor , dacomitinib has a stronger binding force and is not easy to fall off. This strong binding theoretically means dacomitinib may have better and longer-lasting inhibitory effects. In addition, dacomitinib can also inhibit related proteins such as HER2 and HER4, which means that it can not only deal with EGFR mutations, but also other types of mutations, which may help delay drug resistance in some patients.

However, this broad inhibitory effect also comes with some side effects. Side effects of dacomitinib may include diarrhea, rash, nausea and vomiting, abnormal liver function, and thrombocytopenia. In addition, dacomitinib may interact with certain other drugs, such as CYP2D6 substrates and proton pump inhibitors. Therefore, when using dacomitinib, patients need to strictly abide by the doctor's instructions, pay attention to the dosage and storage conditions of the drug, and also pay attention to possible side effects and report to the doctor in a timely manner.

In general, dacomitinib and dacomitinib are the same drug and have shown good efficacy in the treatment of non-small cell lung cancer. In terms of sales, the sales of dacomitinib in the Chinese market have grown rapidly, and it has also entered the national medical insurance catalog. Common specificationsThe price of each box of 15mg*30 tablets may be more than 1,000 yuan.